Login to Your Account

GSK, ImmunoGen Ending Deal To Develop TAP Cancer Drug

By Randall Osborne

Monday, January 27, 2003
Unable to find a retooled deal pleasing to both sides, ImmunoGen Inc. and GlaxoSmithKline plc - which earlier said they were striving to do so - have ended their development agreement for cantuzumab mertansine (huC242-DM1). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription